On behalf of Watson Pharmaceuticals, Skadden has obtained a grant of certiorari from the U.S. Supreme Court, announced on December 7. The Court will review Watson's Eleventh Circuit victory, which rejected the FTC's challenge to the generic drug manufacturer settling reverse-payment lawsuits. Watson sought certiorari because the parties from a competing case in the Third Circuit (K-Dur) simultaneously sought review of a reverse-payment decision. Arguments are expected in the spring of 2013. The K-Dur case will be held by the Court, pending the outcome of this matter.